AddedRisk Factors
Even though the eAPTCs expired at the end of 2025, it is possible that they could be renewed, but the timing of such a decision, and the manner in which the eAPTCs could be renewed, is uncertain and could occur in 2026, which could cause potential disruption and uncertainty for the 2026 OEP. Our failure to effectively anticipate, implement, and manage the operational and regulatory complexities associated with the extension of eAPTCs could also result in a negative member experience and make it difficult to manage membership changes effectively, and negatively affect our reputation, financial condition, and results of operations. If the eAPTCs are renewed, it is possible that a SEP would be initiated which could alter member mix and enrollment levels (including by allowing individuals who enrolled with us during open enrollment to switch to a competitor’s plan), as well as shift consumer behavior. Because these changes would likely occur with limited advance notice and implementation guidance, we may be required to quickly modify our systems, pricing, enrollment processes, and customer support operations to accommodate new eligibility rules, or marketplace workflows. Accelerated timelines increase the risk of operational errors, system disruptions, and member service issues, including delayed or incorrect premium billing, or data reconciliation challenges with federal and state marketplaces. Additionally, sudden enrollment surges may strain our customer service capacity, technology infrastructure, and third-party vendor relationships, potentially reducing service quality. While we are actively planning for various legislative and regulatory outcomes, including full or partial renewal, and have analyzed several operational pathways to mitigate these risks, these efforts may not be sufficient to prevent adverse impacts on our operations and financial results if the APTCs are renewed in whole or in part in 2026, or are renewed on unfavorable terms.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedRisk Factors
CMS announced the resumption of periodic data matching operations at least twice per calendar year to decrease the number of people simultaneously enrolled in Medicaid/CHIP and a subsidized ACA health plan. These initiatives include sharing lists of dually-enrolled individuals with states and state-based exchanges, and for those dually enrolled in Medicaid/CHIP and a federally-facilitated exchange plan, directly notifying them so they can rectify their enrollment status. These provisions may result in a reduction in the number of enrolled individuals in the Health Insurance Marketplace, but we cannot predict with certainty the magnitude of the impact on our membership, overall market morbidity, or our business.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedRisk Factors
•the impact on the morbidity of our members or the broader market member population from ongoing regulatory actions, including actions to improve the integrity in the ACA eligibility and enrollment process (such as the Program Integrity Rules and the OBBBA), the expiration of eAPTCs in 2025, or the potential extension of eAPTCs, in whole or in part, in 2026, if the federal government funds a CSR program, and Medicaid redeterminations;
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedRisk Factors
•the impact on the morbidity of our members or the broader market member population from any shrinkage in the Health Insurance Marketplaces that results from price increases by us or our competitors;
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RemovedRisk Factors
impact our financial condition or require a change in our operating strategies. As a result of these factors, entering new markets or introducing new health plans may decrease our profitability.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•regulatory actions to improve the integrity in the ACA eligibility and enrollment process, such as the measures enacted by the CMS in 2024, make it more difficult for members to enroll in new plans or switch from one plan to another or otherwise retroactively remove members from ACA plans;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the impact on market morbidity of ongoing Medicaid redeterminations and the potential elimination of enhanced APTC;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
estimates are significantly different from actual results, our results of operations and financial position could be adversely affected.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
For the year ended December 31, 2024 we had consolidated net income of $26.1 million and consolidated Adjusted EBITDA of $199.2 million, which was the first time since our inception in 2012 that we achieved profitability on either a consolidated net income or Adjusted EBITDA basis. As of December 31, 2024, we had an accumulated deficit of $2,851.3 million. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Results of Operations-Adjusted EBITDA” for a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP measure.”
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
knew, or it is determined that we should have known, that information we provided to form the basis for a claim for government payment was false or fraudulent, or that we were out of compliance with program requirements considered material to the government’s payment decision.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Health insurers are required to maintain compliance programs to prevent, detect and remediate fraud, waste, and abuse, and are often the subject of fraud, waste, and abuse investigations and audits.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, on May 12, 2022, a securities class action lawsuit against the Company, certain of its directors and officers, and the underwriters that participated in the Company’s initial public offering (“IPO”) was commenced in the United States District Court for the Southern District of New York, captioned Carpenter v. Oscar Health, Inc., et al., Case No. 1:22-CV-03885 (S.D.N.Y.) (the “Securities Action”). The amended complaint, filed on December 6, 2022, primarily alleges that the Company failed to disclose in its IPO registration statement purportedly inadequate controls and systems in connection with the risk adjustment data validation audit for 2019, in violation of Sections 11 and 15 of the Securities Act, and that this alleged omission caused losses and damages for members of the putative class. The amended complaint seeks unspecified compensatory damages as well as interest, fees and costs.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
As initially disclosed in Part II, Item 9A, “Controls and Procedures,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, in connection with our audit of the Consolidated Financial Statements for the year ended December 31, 2021, we identified a material weakness in our internal control over financial reporting related to information technology general controls.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
and could make our Class A common stock less attractive to other investors. As a result, the market price of our Class A common stock could be adversely affected.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
The obligations associated with being a public company require significant resources and management attention.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
As a public company, we face increased legal, accounting, administrative, and other costs and expenses that we did not incur as a private company. We have incurred, and expect to continue to incur, significant costs related to operating as a public company. We are subject to the Exchange Act, the rules and regulations implemented by the SEC, the Sarbanes-Oxley Act, the Dodd-Frank Act, the Public Company Accounting Oversight Board (the “PCAOB”), and the rules and standards of the NYSE, each of which imposes additional reporting and other obligations on public companies.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
Bertolini, our Chief Executive Officer and a member of our board of directors, Mario Schlosser, our Co-Founder, President of Technology and Chief Technology Officer and a member of our board of directors, and Joshua Kushner, our Co-Founder, Vice Chairman and a member of our board of directors, the “Co-Founders”), the other members of our senior management team, highly-specialized technology and insurance experts, and key technical employees, as well as other highly qualified personnel.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
As we expand our customer base and enter into +Oscar platform arrangements, or additional lines of business, such as those in connection with our acquisition of Lucie, Inc., IHC Specialty Benefits, Inc., and Healthinsurance.org, LLC, we may become subject to an increasingly complex array of data privacy and security laws and regulations, further increasing our cost of compliance and doing business. business, as well as clients’ expectations for privacy and security, which are relevant to our ability to compete in this market.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
We maintain a significant investment portfolio of cash equivalents and primarily short-term investments in a variety of securities, which are subject to general credit, liquidity, market, and interest rate risks and risks, meaning the value of our fixed-income holdings will decline in value generally decrease if interest rates decrease or one of rise, and a sustained decline in interest rates will reduce the issuers’ credit ratings is reduced. returns available when we reinvest maturing funds.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
In such cases, we conduct certain outreach procedures under our policies and refer instances of potentially unauthorized enrollment to the appropriate authorities for potential rescission, which may also entail retroactive adjustment of membership numbers. numbers or rescission of federal APTCs, and if such rescissions are effected following the calculation or payment of our risk adjustment transfer payable or the settlement of claims, the resulting financial impact on us could be compounded.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition to the restrictions imposed by our The 2026 Revolving Credit Facility, the Investment Agreement that we entered into in connection with our issuance of the 2031 Notes contains covenants, which, subject to certain conditions, limitations and exceptions, restrict restricts our ability to refinance our indebtedness and incur additional indebtedness.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
The terms of our senior secured credit agreement with Wells Fargo Bank, National Association, as administrative agent, and certain other lenders 2026 Credit Agreement for the 2026 Revolving Credit Facility in the aggregate principal amount of $115 million, may restrict us and our subsidiaries from engaging in specified types of transactions.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Medicaid redeterminations began on April 1, 2023 and CMS also announced an SEP that began March 31, 2023 and ended November 30, 2024. 2024 to facilitate enrollment in the ACA by individuals who lost Medicaid coverage under the redetermination process.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although The eAPTCs expired at the enhanced APTCs have been extended through end of 2025, the and this expiration, as well as any future elimination or reduction of the enhanced APTCs, or other APTCs or subsidies, could make such coverage unaffordable to some individuals and thereby reduce overall participation in the Health Insurance Marketplaces and and/or our membership.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Bertolini, our Chief Executive Officer and a member of our board of directors, Mario Schlosser, our Co-Founder, President of Technology and Chief Technology Officer and a member of our board of directors, and Joshua Kushner, our Co-Founder, Vice Chairman and a member of our board of directors, the other members of our senior management team, highly-specialized technology and insurance experts, and key technical employees, as well as other highly qualified personnel. directors (Mr.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
If one of the states in which we operate were to experience a large-scale natural disaster, a significant terrorist attack, or some other large-scale event affecting the health of a large number of our members, our covered medical expenses in that state would rise, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore Furthermore, we have, have entered into, and we may in the future, future enter into into, tax allocation agreements between our Parent parent company and our insurance subsidiaries, Health Insurance Subsidiaries, which agreements require regulatory approval, and there is no guarantee that Parent our parent company will be able to obtain the tax sharing payments from its subsidiaries Health Insurance Subsidiaries under such agreements.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedRisk Factors
For each of the years ended December 31, 2024 2025 and 2023, 2024, approximately 97% 98% of our revenue was derived from sales of health plans subject to regulation under the ACA, primarily comprised of policies directly purchased by individuals and families and secondarily comprised of policies purchased by small employers and provided to their employees as a benefit. families.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For example, one of our vendors in the past experienced a data security incident which required us to devote significant time and resources towards assessing the impact on our operations and member data and to secure alternative vendor relationships, even though the incident was ultimately determined not to not directly result in a breach of our members’ data.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, given the costs, effort, and risks of obtaining patent protection, including the requirement to ultimately disclose the invention to the public, we continue not to choose not to seek patent protection.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
Our technology drives superior experiences, deep engagement, and high-value clinical care, earning us the trust of approximately 2.0 million effectuated members (“members”) as of December 31, 2025. Effectuated members are those who are actively enrolled in one of the Company’s plans and whose required premium payments have either been made or are within the payment grace period.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, we also acquired early-stage businesses with capabilities to help us power Individual Coverage Health Reimbursement Arrangements (“ICHRA”) and further diversify the Company. These assets include Lucie, Inc., a direct enrollment technology platform; IHC Specialty Benefits, Inc., an individual market brokerage; and Healthinsurance.org, LLC, a consumer education website.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
Earnings (loss) from operations is the Company's Total revenue less Total operating expenses. We believe Earnings (loss) from operations is an important primary metric for assessing operating performance.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
•The Centers for Medicare & Medicaid Services (“CMS”) is increasingly focused on improving integrity in the Health Insurance Marketplaces’ eligibility and enrollment process, and we expect this focus to continue. During the second half of 2024, CMS enacted new measures to respond to increases in unauthorized changes in consumer enrollments by agents and brokers and to reduce consumer burdens related to unauthorized enrollments. While these measures are important to prevent unauthorized enrollments, they may also make it more difficult for individuals to complete valid enrollments in new plans, switch from one plan to another, or obtain Advanced Premium Tax Credits (“APTCs”). In addition, on June 25, 2025, CMS issued a rule that created stricter eligibility verification processes for APTCs, as well as other requirements related to ACA plan enrollment, including shorter OEPs and the suspension of certain special enrollment periods (“SEPs”), such rules, the “Program Integrity Rules”. On August 22, 2025, in connection with City of Columbus vs. Kennedy, in which the plaintiffs alleged certain provisions of the Program Integrity Rules are contrary to law, a federal district court in Maryland issued a nationwide stay on several provisions of the Program Integrity Rules pending a final ruling on the merits of the case. The litigation did not conclude before 2026 and CMS confirmed that the stayed provisions were not in effect during the 2026 open enrollment period (“OEP”). Many of the stayed provisions would have otherwise impacted enrollment processes and APTC eligibility during the 2026 OEP. For example, the court stayed the application of a $5 monthly premium to enrollees in $0 premium plans who do not actively reenroll during open enrollment. If the stayed provisions are reinstated in 2026, they are expected to impact enrollment processes and APTC eligibility during the 2027 and other future OEPs. Provisions of the Program Integrity Rules unaffected by the stay became effective on August 25, 2025. Furthermore, on July 4, 2025, the President signed into law the One Big Beautiful Bill Act (the “OBBBA”) which, among other relevant matters, limits the eligibility of APTCs for certain populations, and requires additional verification procedures to confirm member eligibility for APTCs.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
•Based on the most recent data from CMS, enrollment in the Health Insurance Marketplaces decreased from the 2025 OEP to the 2026 OEP, which we believe was due to the expiration of the eAPTCs, and the implementation of the Program Integrity Rules and the OBBBA, but such data is preliminary and may be inaccurate or incomplete, and the actual level of enrollment in the Health Insurance Marketplace in 2026 will not be known until later in 2026. We expect that these regulatory and legislative developments could continue to impact the size of the Health Insurance Marketplaces and our membership in future years. Any resulting market contraction could negatively impact market morbidity.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
•Medicaid redeterminations began on April 1, 2023 and CMS announced an SEP that began March 31, 2023 and ended November 30, 2024 to facilitate enrollment in the ACA by individuals who lost Medicaid coverage under the redetermination process. Our understanding is that in 2024 most states substantially completed the unwinding-related renewals for beneficiaries enrolled in Medicaid or Children's Health Insurance Program (“CHIP”). We believe these Medicaid redeterminations previously contributed to increases in our membership in 2024; however, we do not believe that we experienced significant growth in our membership from the Medicaid redetermination process in 2025. We believe that members who have enrolled in the ACA through the Medicaid redetermination process have increased the overall morbidity of the Health Insurance Marketplace.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
The Trump administration has indicated that new tariffs may be imposed on a variety of products relevant to our business, including certain pharmaceutical products and ingredients and medical devices and supplies imported into the United States. If such tariffs are imposed, the potential impact could include, among other things, higher costs for medical providers and facilities, higher pharmaceutical prices, higher costs of medical devices, and supplies and shortages of certain medicines and medical supplies. Shortages in medicines and supplies may also impact the health of our members, which in turn may result in higher medical costs. The unprecedented nature of these types of tariffs, as well as uncertainty around their implementation, could impact our ability to accurately estimate and effectively manage the impact on our medical expenses, which in turn could adversely affect our results of operations and financial position. For additional details, see Part I, Item 1A. “Risk Factors-Most Material Risks to Us-Failure to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs could negatively affect our financial position, results of operations, and cash flows” and “Risk Factors-Risks Related to the Regulatory Framework That Governs Us-Changes in laws, regulations or rules relating to taxes or tariffs could adversely affect us.”
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
Other revenues include revenue earned through brokerage, enhanced direct enrollment (“EDE”) platform, and market education services, fees for services performed via the +Oscar platform, revenue sharing from virtual credit card rebates, and sublease income.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, the Company received conversion notices from certain of the Initial Purchasers to convert a total of $20.0 million in aggregate principal amount of the 2031 Notes. The Company elected to issue approximately 2.4 million shares of Class A common stock to settle these conversions.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
On November 3, 2025, the Company and Dragoneer entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which, until December 14, 2025, Dragoneer could elect to exchange up to $250.0 million aggregate principal amount of the 2031 Notes, representing the balance of its 2031 Notes, for aggregate consideration consisting of (A) a number of shares of Class A common stock based on the conversion rate set forth in the 2031 Indenture, and (B) up to $17.8 million, payable in shares of Class A common stock and/or cash, pursuant to the terms of the Exchange Agreement and subject to the satisfaction of certain conditions. In November 2025, Dragoneer exchanged a total of $250.0 million aggregate principal amount of their 2031 Notes in exchange for approximately 30.1 million shares of the Company’s Class A common stock. As a result of this conversion, the net carrying amount of 2031 Notes, including unamortized debt discount and issuance costs of $12.9 million, were transferred to additional paid-in capital. Additionally, with the exchange, Dragoneer also received an inducement payment totaling $17.8 million, of which $4.4 million was paid in cash and the remaining $13.3 million was settled through the issuance of approximately 0.7 million additional shares of Class A common stock. The Company recognized the inducement payment as Other expense in its Consolidated Statements of Operations.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the Exchange Agreement and the related transactions, as of November 5, 2025, the debt covenants in the Investment Agreement, as amended, were extinguished, and the 2030 Notes ceased to be subordinated to the 2031 Notes.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
AddedMD&A
On September 18, 2025, the Company issued $410.0 million aggregate principal amount of convertible senior notes due 2030 (the “2030 Notes”). The 2030 Notes were issued pursuant to an indenture (the “2030 Indenture”), dated as of September 18, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RemovedMD&A
Adjusted Earnings before Interest, Taxes, Depreciation, and Amortization (“Adjusted EBITDA”)
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Adjusted EBITDA is defined as Net income (loss) for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), and depreciation and amortization, as further adjusted for stock-based compensation and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•as a measurement of operating performance because it assists us in comparing the operating performance of our business on a consistent basis, as it removes the impact of items not directly resulting from our core operations;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•for planning purposes, including the preparation of our internal annual operating budget and financial projections;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•to evaluate the performance and effectiveness of our operational strategies; and
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net income (loss), we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for Net income (loss) or other financial statement data presented in our Consolidated Financial Statements as indicators of financial performance. A reconciliation of Adjusted EBITDA from Net income (loss) is provided under “Results of Operations-Adjusted EBITDA”.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Material Risks to Us–Any changes to the ACA and its regulations could materially and adversely affect our business, results of operations, and financial condition.”
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
•The Consolidated Appropriations Act of 2023 delinked the Medicaid continuous coverage from the end of the PHE for COVID-19, and Medicaid redeterminations began on April 1, 2023 and CMS announced an SEP that began March 31, 2023 and ended November 30, 2024. The Medicaid redeterminations have contributed to increases in our membership. While CMS announced in 2024 that all unwinding-related renewals for beneficiaries enrolled in CHIP must be completed no later than December 31, 2025, our understanding is that the majority of states have now substantially completed their unwinding processes. We anticipate that any future impact on our membership in connection with ACA enrollments due to the unwinding of the Medicaid continuous enrollment condition will not be as significant as the membership growth we experienced in plan year 2024. For additional details, see “Business–Government Regulation–Ongoing Requirements and Changes to the ACA” and “Risk Factors–Most Material Risks to Us–Failure to accurately estimate our incurred medical expenses or effectively manage our medical costs or related administrative costs could negatively affect our financial position, results of operations, and cash flows.”
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
is also uncertainty associated with changes in other carriers operations, which may impact the ultimate degree of market level risk. Actual risk adjustment calculations and transfers could materially differ from our assumptions.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Services and other revenue includes primarily revenue earned from administrative services performed as part of the +Oscar platform, as well as sublease income.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(1) Adjusted EBITDA is a non-GAAP measure. See “-Adjusted EBITDA” below for a reconciliation to net income (loss), the most directly comparable GAAP measure, and "-Overview-Adjusted EBITDA" for information regarding our use of Adjusted EBITDA.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
On December 28, 2023, we entered into a third amendment to our senior secured credit agreement (the “Third Amendment”), with Wells Fargo Bank, National Association, as lender and the administrative agent, and certain other lenders party thereto from time to time (collectively the “Lenders”), time, and Oscar Management Corporation, as a subsidiary guarantor, which amended the senior secured credit agreement, dated as of February 21, 2021 (as amended by amended, the First Amendment to Credit Agreement, dated as of January 27, 2022, and as further amended by the Second Amendment to Credit Agreement, dated as of July 21, 2023, the “Credit Agreement” and as amended by the Third Amendment, the “Amended “2021 Amended Credit Agreement”).
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in thousands, except percentages) 2025 2024 2023 Revenue Premium $ 11,469,893 $ 8,971,259 $ 5,686,069 Investment income 202,941 185,729 155,447 Services and other Other revenues 28,593 20,576 21,353 Total revenue 11,701,427 9,177,564 5,862,869 Operating Expenses Medical 10,019,025 7,332,589 4,642,024 Selling, general, and administrative 2,049,867 1,755,565 1,425,766 Depreciation and amortization 28,892 32,145 30,694 Total operating expenses 12,097,784 9,120,299 6,098,484 Earnings (loss) from operations (396,357) 57,265 (235,615) Interest expense 17,601 23,734 24,603 Other expenses (income) 23,339 105 7,082 Earnings (loss) before income taxes (437,297) 33,426 (267,300) Income tax expense 5,606 7,305 3,294 Net income (loss) (442,903) 26,121 (270,594) Less:
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
We regularly review our Total Revenue, MLR, revenue, Medical Loss Ratio (“MLR”), Selling, General general, and Administrative Expense Ratio administrative expense ratio (“SG&A Expense Ratio”), expense ratio”), Earnings (loss) from operations, and Net Income income (loss) attributable to Oscar Health Inc., and Adjusted EBITDA, a non-GAAP financial metric, Health, Inc. to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
For more detail related information on our 2030 Notes, including details relating to our medical claims expenses, repurchase, redemption and conversions of the 2030 Notes, and the Capped Call Transactions, see Note 2 “Note 9 - Summary of Significant Accounting Policies Debt” to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Healthcare costs in the years ended December 31, 2025 and 2024 included a favorable healthcare claim development related to prior years years, net of reinsurance of $239.5 million and $164.7 million (net of reinsurance) and an unfavorable health claim development of $19.8 million (net of reinsurance) for the year ended December 31, 2023. million, respectively.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
Our medical expenses are impacted by unit costs and utilization, as well as seasonal effects of on medical costs, such as the utilization members pay their contractual claims portion of claims responsibility, meeting their deductibles and out-of-pocket maximums over the course of the policy year, which shift more costs to us in the second half of the year as we pay a higher proportion of covered claims costs, and the number of days and holidays in a given period. costs.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
The SG&A Expense Ratio improved 520 decreased 160 basis points year over year for the year ended December 31, 2024, 2025, primarily due to improved greater fixed cost leverage leverage, lower exchange fee rates, and variable disciplined cost efficiencies. management, partially offset by the impact of higher risk adjustment as a percentage of premium.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
The 2031 Notes may be converted at the option election of the holders, on or after August 31, 2031, holders under certain circumstances, including if we call the 2031 Notes for redemption, redemption or upon the satisfaction of a Class A common stock sale price or 2031 Note trading price condition, or upon certain corporate events. condition.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
For additional details relating to the 2031 Notes, see Note 9 - Debt to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K, and, “Risk Factors–Risks Related to Indebtedness–Our debt obligations contain restrictions that impact our business and expose us to risks that could materially adversely affect our liquidity and financial condition” and “Risk Factors–Risks Related to Indebtedness–We may be unable to raise the funds necessary to repurchase our outstanding 2031 Notes for cash following a fundamental change or on the optional repurchase dates, or to pay any cash amounts due upon conversion, and our other indebtedness may limit our ability to repurchase the 2031 Notes or pay cash upon their conversion.”
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
The combined statutory capital and surplus of our health insurance subsidiaries Health Insurance Subsidiaries was estimated to be approximately $1,242.7 million $1.0 billion as of December 31, 2025, and $1.2 billion as of December 31, 2024, and it was $800.6 million as of December 31, 2023, respectively, which was in compliance with and in excess of the minimum capital requirements for each period.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
There is a higher degree of uncertainty associated with estimates of risk adjustment transfers at the beginning of earlier in the policy year or, in the case of SEP driven enrollment, throughout the policy year, resulting from composition of the fact that risk score being scores are based on concurrent lagged claim data.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024 2025 and December 31, 2023, 2024, total cash and cash equivalents and investments held by the holding company these entities was $189.8 $414.2 million and $234.1 $189.8 million, respectively, of which $12.8 $14.7 million and $12.6 $12.8 million was restricted for 2024 as of December 31, 2025 and 2023, 2024, respectively.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new
Quiet changesMD&A
During the periods presented in the financial statements contained elsewhere in this Annual Report on Form 10-K, certain regulatory developments have impacted, and may are expected to continue to impact, our results of operations.
Read it in 10-K Feb 13, 2026 at sec.govopen_in_new